Aurinia Pharmaceuticals Inc
AUPH15.150USD
-0.180-1.17%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.00BMarket Cap
26.33P/E TTM
More Details of Aurinia Pharmaceuticals Inc Company
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Aurinia Pharmaceuticals Inc Info
Ticker SymbolAUPH
Company nameAurinia Pharmaceuticals Inc
IPO dateJul 16, 2001
CEOGreenleaf (Peter S)
Number of employees130
Security typeOrdinary Share
Fiscal year-endJul 16
Address#140, 14315 - 118 Avenue
CityEDMONTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT5L 4S6
Phone12507442487
Websitehttps://www.auriniapharma.com
Ticker SymbolAUPH
IPO dateJul 16, 2001
CEOGreenleaf (Peter S)
Company Executives of Aurinia Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
720.08K
+52215.00%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
184.38K
+8173.00%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-2825.00%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-142976.00%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey A. Bailey
Mr. Jeffrey A. Bailey
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
720.08K
+52215.00%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
184.38K
+8173.00%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-2825.00%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-142976.00%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Jan 7
Updated: Wed, Jan 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
8.59%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.72%
New Enterprise Associates (NEA)
3.01%
Arrowstreet Capital, Limited Partnership
2.56%
Other
76.16%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
8.59%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.72%
New Enterprise Associates (NEA)
3.01%
Arrowstreet Capital, Limited Partnership
2.56%
Other
76.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
15.27%
Hedge Fund
15.04%
Investment Advisor
12.88%
Corporation
4.96%
Research Firm
3.21%
Venture Capital
3.03%
Individual Investor
2.48%
Pension Fund
0.78%
Bank and Trust
0.31%
Other
42.05%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
445
66.60M
50.51%
+1.59M
2025Q3
456
66.87M
50.55%
+7.38M
2025Q2
441
59.25M
53.54%
-3.86M
2025Q1
434
64.06M
48.83%
-3.20M
2024Q4
431
60.29M
49.51%
-113.45K
2024Q3
429
60.37M
47.88%
+2.19M
2024Q2
432
58.67M
47.42%
+718.51K
2024Q1
426
57.94M
45.47%
-7.82M
2023Q4
439
56.12M
43.33%
+3.78M
2023Q3
448
52.25M
45.32%
-2.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
11.33M
8.59%
+1.30M
+12.96%
Sep 30, 2025
ILJIN SNT Co., Ltd.
6.54M
4.96%
-984.75K
-13.10%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
6.22M
4.72%
-241.10K
-3.73%
Sep 30, 2025
New Enterprise Associates (NEA)
3.97M
3.01%
--
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
3.37M
2.56%
+2.30M
+213.54%
Sep 30, 2025
State Street Investment Management (US)
2.69M
2.04%
-101.33K
-3.63%
Sep 30, 2025
Two Sigma Investments, LP
1.83M
1.39%
+1.48M
+417.21%
Sep 30, 2025
The Vanguard Group, Inc.
1.53M
1.16%
-163.37K
-9.65%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.49M
1.13%
-91.36K
-5.79%
Sep 30, 2025
Marshall Wace LLP
1.48M
1.12%
+1.38M
+1272.51%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.56%
Janus Henderson Small Cap Growth Alpha ETF
2.33%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.09%
ALPS Medical Breakthroughs ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.26%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.26%
SPDR S&P International Small Cap ETF
0.2%
Vanguard US Multifactor ETF
0.18%
Invesco Nasdaq Biotechnology ETF
0.17%
Avantis US Small Cap Equity ETF
0.16%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.56%
Janus Henderson Small Cap Growth Alpha ETF
Proportion2.33%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion1.09%
ALPS Medical Breakthroughs ETF
Proportion0.7%
ProShares Ultra Nasdaq Biotechnology
Proportion0.26%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.26%
SPDR S&P International Small Cap ETF
Proportion0.2%
Vanguard US Multifactor ETF
Proportion0.18%
Invesco Nasdaq Biotechnology ETF
Proportion0.17%
Avantis US Small Cap Equity ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aurinia Pharmaceuticals Inc?
The top five shareholders of Aurinia Pharmaceuticals Inc are:
Tang Capital Management, LLC holds 11.33M shares, accounting for 8.59% of the total shares.
ILJIN SNT Co., Ltd. holds 6.54M shares, accounting for 4.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.22M shares, accounting for 4.72% of the total shares.
New Enterprise Associates (NEA) holds 3.97M shares, accounting for 3.01% of the total shares.
Arrowstreet Capital, Limited Partnership holds 3.37M shares, accounting for 2.56% of the total shares.
Tang Capital Management, LLC holds 11.33M shares, accounting for 8.59% of the total shares.
ILJIN SNT Co., Ltd. holds 6.54M shares, accounting for 4.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.22M shares, accounting for 4.72% of the total shares.
New Enterprise Associates (NEA) holds 3.97M shares, accounting for 3.01% of the total shares.
Arrowstreet Capital, Limited Partnership holds 3.37M shares, accounting for 2.56% of the total shares.
What are the top three shareholder types of Aurinia Pharmaceuticals Inc?
The top three shareholder types of Aurinia Pharmaceuticals Inc are:
Tang Capital Management, LLC
ILJIN SNT Co., Ltd.
BlackRock Institutional Trust Company, N.A.
Tang Capital Management, LLC
ILJIN SNT Co., Ltd.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Aurinia Pharmaceuticals Inc (AUPH)?
As of 2025Q4, 445 institutions hold shares of Aurinia Pharmaceuticals Inc, with a combined market value of approximately 66.60M, accounting for 50.51% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.04%.
What is the biggest source of revenue for Aurinia Pharmaceuticals Inc?
In FY2024, the -- business generated the highest revenue for Aurinia Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
